Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 12/20 | 0.48 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5228683 | 0.84 | HDAC1 (0.47) | HDAC1HDAC3CYP2C9SLC6A4SLC6A3 | |
| SCHEMBL5222728 | 0.81 | PTPN11 (0.56) | HDAC1PTPN11 | |
| SCHEMBL5226816 | 0.80 | HDAC3 (0.38) | HDAC1HDAC3HDAC2 | |
| SCHEMBL15924166 | 0.75 | HDAC3 (0.49) | HDAC1HDAC3HDAC2 | |
| SCHEMBL22519008 | 0.73 | CHRM1 (0.46) | SLC6A7CHRM4 | |
| SCHEMBL5229928 | 0.72 | NAMPT (0.43) | HDAC1 | |
| SCHEMBL25383375 | 0.72 | SLC6A7 (0.45) | SLC6A7CHRM4 | |
| SCHEMBL3548310 | 0.72 | SLC6A7 (0.39) | SLC6A7CHRM4PTPN11KITDGAT2 | |
| Methane SCHEMBL27601733 | 0.72 | MDM4 (0.46) | HDAC1 | |
| SCHEMBL27601739 | 0.71 | SMN1; SMN2 (0.47) | HDAC1HDAC3HDAC2PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501508-B1 | INHIBITORS OF HISTONE DEACETYLASE | ASTRAZENECA AB (SE) | 2007-02-21 | — | — | EP | disclosed |
| US-20050222410-A1 | Inhibitors of histone deacetylase | ASTRAZENECA AB (SE) | 2005-10-06 | — | — | US | disclosed |
| EP-1501508-A1 | INHIBITORS OF HISTONE DEACETYLASE | Astrazeneca AB (SE) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003092686-A1 | INHIBITORS OF HISTONE DEACETYLASE | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222410-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | HDAC1 1/4885SLC6A7 2530/4885HDAC3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.